Alzamend Neuro Inc (NASDAQ:ALZN) CEO and director Stephan Jackman speaks to Proactive about the two therapeutics the company is currently working to transition targeting Alzheimer’s disease and psychiatric disorders from clinical/non-clinical stages and towards full commercialization.
Jackman told Proactive that more than 6 million Americans suffer from Alzheimer’s, with a similar number of suffering from bipolar disorder. More than 21 million people in the United States suffer from depression, while about 13 million are affected by post-traumatic stress disorder.
“The patient population for this one product, our lead drug candidate, is a little over 43 million just in the United States,” Jackman added. “Globally that’s about 600 million people.”